Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2022
Price :
$35
*
At a glance
- Drugs BMS-986263 (Primary)
- Indications Hepatic fibrosis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 04 Oct 2021 Results published in the Hepatology
- 29 Aug 2020 Results assessing Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis presented at The International Liver Congress 2020
- 09 Dec 2019 Status changed from recruiting to completed.